Donny Wynn, MD
Endocrinology, Diabetes & Metabolism · Oklahoma City, OKNPI 1942341573
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.8% of the total across 519 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 37 manufacturers, the largest accounting for just 9.0% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $3,390, more than ten times the $90 reported in 2019.
Across 519 payments — averaging $21.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Corcept Therapeutics$992
- Dexcom, Inc.$855
- Lilly USA, LLC$850
- Xeris Pharmaceuticals, Inc.$794
- Abiomed$670
- Amgen$626
- plus $6K from 31 others
What the payments were for
- Food & beverage$11,017100%
- Education$230%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Corcept Therapeutics | 41 | $992 |
| Dexcom, Inc. | 43 | $855 |
| Lilly USA, LLC | 49 | $850 |
| Xeris Pharmaceuticals, Inc. | 42 | $794 |
| Abiomed | 5 | $670 |
| Amgen(2 entities) | 31 | $626 |
| Bayer | 45 | $574 |
| Novo Nordisk | 32 | $496 |
| Sanofi-aventis U.S. LLC | 22 | $451 |
| Boehringer Ingelheim | 24 | $412 |
| Tandem Diabetes Care, Inc. | 17 | $399 |
| Abbott | 19 | $384 |
| AbbVie(2 entities) | 17 | $334 |
| Insulet Corporation | 15 | $332 |
| Ascensia Diabetes Care US Inc. | 7 | $286 |
| Medtronic | 4 | $257 |
| IBSA Pharma Inc. | 11 | $235 |
| Recordati_rare_diseases_inc. | 10 | $218 |
| BETA Bionics, Inc. | 10 | $184 |
| Sequel Med Tech, LLC | 10 | $181 |
| Chiesi USA, Inc. | 7 | $161 |
| Mannkind Corporation | 8 | $152 |
| Echosens North America, Inc. | 1 | $125 |
| Radius Health, Inc. | 5 | $122 |
| Cequr Corporation | 3 | $120 |
| Ascendis Pharma Endocrinology Inc | 5 | $118 |
| Antares Pharma, Inc. | 6 | $101 |
| Nevro Corp. | 4 | $94 |
| Novartis | 5 | $92 |
| AstraZeneca(2 entities) | 4 | $89 |
| Neurocrine Biosciences, Inc. | 3 | $75 |
| Kyowa Kirin, Inc. | 3 | $69 |
| Astellas Pharma US Inc | 4 | $62 |
| Amneal Pharmaceuticals LLC | 2 | $39 |
| Pfizer | 2 | $35 |
| Lifescan, Inc. | 2 | $35 |
| Ultragenyx Pharmaceutical Inc. | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Impella$670
- MINIMED 780G$228
- EVERSENSE E3 SMART TRANSMITTER KIT$127
- FibroScan$125
- DEXCOM G7 GSS (161)$117
- Korlym$113
- CeQur Simplicity$106
How this compares
$11,041 in reported general payments places this provider in the 80th percentile of 61 endocrinology, diabetes & metabolism providers in Oklahoma.
See all endocrinology, diabetes & metabolism providers in Oklahoma →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 416 | $633,395 |
| MounjaroTirzepatide | 349 | $465,604 |
| JardianceEmpagliflozin | 129 | $150,323 |
| Tresiba Flextouch U-200Insulin Degludec | 59 | $110,803 |
| FarxigaDapagliflozin Propanediol | 79 | $89,772 |
| Tresiba Flextouch U-100Insulin Degludec | 93 | $79,501 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 32 | $63,791 |
| Humalog Kwikpen U-200Insulin Lispro | 12 | $61,622 |
| JanuviaSitagliptin Phosphate | 47 | $41,495 |
| TrulicityDulaglutide | 34 | $40,391 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 28 | $37,550 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 38 | $35,846 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 12 | $29,941 |
| Humalog Kwikpen U-100Insulin Lispro | 79 | $28,150 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 38 | $27,980 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $496 | $660,091430 claims |
| Lilly USA, LLCMounjaro, Trulicity | $850 | $505,994383 claims |
| Boehringer IngelheimJardiance, Tradjenta | $412 | $163,257142 claims |
| AstraZenecaFarxiga | $89 | $89,77279 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $451 | $29,94112 claims |
| AbbVieSynthroid, Armour Thyroid | $334 | $12,379146 claims |
| PfizerPremarin | $35 | $8,32918 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $39 | $6,978621 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 61 endocrinology, diabetes & metabolism providers in Oklahoma.
Other endocrinology, diabetes & metabolism in Oklahoma City
- Christian MangrumOklahoma City$54K
- Robert ScofieldOklahoma City$15K
- Cheryl BlackOklahoma City$8K
- Diana KennedyOklahoma City$8K
- Ali TipuOklahoma City$8K
- Amanda LagrecaOklahoma City$7K
- Bassam ArodakOklahoma City$6K
- Myrto EliadesOklahoma City$5K
- Hamsa AljumailiOklahoma City$5K
- Modhi GudeOklahoma City$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.